Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Shedding Light on Inflammation

By Drug Discovery Trends Editor | February 23, 2016

Endomucin (red) expression in normal, non-injured tissue. Endomucin plays a key role in maintaining a non-inflammatory endothelial cell surface by preventing adhesion of white blood cells to the vascular surface. Credit: Mass Eye and EarResearchers from the Harvard Medical School Department of Ophthalmology and the Schepens Eye Research Institute of Mass. Eye and Ear have gained new insight into how a noninflammatory state is maintained in the body. Their work focuses on the role of endomucin, a key molecule with anti-adhesive properties that encourage neutrophils—prevalent white blood cells that sense signals of injury—to travel past the vascular endothelium. Their findings, published in Nature Communications, represent a new understanding of inflammation.
 
Blood cells move through the circulatory system from the heart through the arteries to the smallest capillaries, and then to the veins and back to the heart. The vascular system is lined with the endothelium, a thin layer of cells that serve as an interface between the blood and the tissues. When there is an injury or disease process, the body sends out signals that recruit circulating neutrophils to stick to the endothelium; the neutrophils then migrate between the endothelial cells and pass into tissue. The accumulation of neutrophils and other white blood cells in the injured tissues facilitates an increase in adhesive molecules on the surface of the small vessels in injured tissue.
 
The research, led by Patricia D’Amore, the HMS Charles L. Schepens Professor of Ophthalmology, and Pablo Argüeso, HMS associate professor of ophthalmology, both at Schepens, shows that in healthy, noninflamed tissue, endomucin plays a critical role in preventing the neutrophils from sticking to the endothelium. During inflammatory conditions, however, the endomucin on the endothelial cell surface is dramatically reduced so that the levels of pro-adhesive molecules on the endothelium increase, resulting in neutrophil accumulation. The researchers showed in both tissue culture and animal models that the adherence and infiltration of inflammatory cells could be blocked by experimentally expressing excess endomucin in the vascular endothelium.
 
“Until now, researchers studying the role of the endothelium in inflammation have primarily focused on pro-adhesive molecules that trap the white blood cells at the site of injury,” said Argüeso. “We have now shown that there is also a mechanism to maintain an anti-adhesive surface on the vascular endothelium. Endomucin acts to prevent the inflammatory cells from adhering to blood vessels. The fact that endomucin decreases during inflammation suggests that this molecule may be as important in transforming the endothelial cell surface to a pro-inflammatory state as the elevation in adhesive molecules.”
 
Most current treatments for inflammation involve targeting the activities of cytokines and inflammatory mediators, which have risks and limitations. This new knowledge may be used to develop treatments for inflammation by promoting the expression of endomucin to prevent the movement of inflammatory cells from the capillaries into inflamed tissues. 
 
“In our experiments, we have shown that there is potential to interfere with inflammation by promoting the expression of endomucin,” said Argüeso. “Many diseases have an inflammatory component, and by targeting this molecule we believe we can reduce unnecessary inflammation.”
 
This study was supported by the Schepens Eye Research Institute co-investigative pilot project initiative, the National Eye Institute (grants EY014847 and EY05318) and the National Heart, Lung, and Blood Institute (grants HL036028, HL094706 and HL123658).
 
Source: Harvard Medical School

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE